FDA-Approved GLP-1 Receptor Agonists for Obesity
For obesity treatment, you can prescribe liraglutide 3.0 mg daily (approved 2014) or semaglutide 2.4 mg weekly subcutaneous (approved 2021), with semaglutide demonstrating superior weight loss outcomes. 1
Currently Available Options
Semaglutide 2.4 mg Weekly (Subcutaneous)
- Most effective option: Produces 16.9% average weight reduction at 68 weeks 1
- FDA-approved for adults (2021) and adolescents ≥12 years (2022) 1
- Titration schedule: Start 0.25 mg weekly × 4 weeks, then increase monthly to 0.5 mg, 1.0 mg, 1.7 mg, reaching maintenance dose of 2.4 mg at 16 weeks 2
- Additional benefit: Recently approved for secondary cardiovascular risk reduction, with 20% reduction in major adverse cardiovascular events in the SELECT trial 1
Liraglutide 3.0 mg Daily (Subcutaneous)
- Second-line option: Produces 8.0% average weight reduction at 56 weeks 1
- FDA-approved for adults (2014) and adolescents ≥12 years (2020) 1
- Titration schedule: Start 0.6 mg daily × 7 days, then increase weekly by 0.6 mg increments (1.2 mg, 1.8 mg, 2.4 mg) until reaching maintenance dose of 3.0 mg at 4 weeks 2
- Cardiovascular data: The LEADER trial showed MACE reduction at 1.8 mg dose in patients with type 2 diabetes, but no cardiovascular outcomes trial exists for obesity without diabetes 1
Emerging Options (Not Yet FDA-Approved for Obesity)
Oral semaglutide at 50 mg daily demonstrated 17.1% weight reduction at 68 weeks in the OASIS-1 trial, though currently only the oral formulation at 14 mg is FDA-approved for type 2 diabetes 1, 3
Critical Implementation Details
Dosing Adjustments for Missed Doses
- 2 consecutive doses missed: Resume at same dose if previously well-tolerated; otherwise lower the dose 2
- 3+ consecutive doses missed: Restart the full titration schedule 2
Early Response Prediction
For both agents, achieving ≥4-5% weight loss at 16 weeks predicts successful long-term response (10.8% vs 3.0% final weight loss for responders vs non-responders) 1
Key Contraindications and Precautions
- Do not combine with other GLP-1 RAs or DPP-4 inhibitors 2
- Contraindicated: Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 2
- Caution with insulin/sulfonylureas: Adjust doses and monitor for hypoglycemia 2
- Delayed gastric emptying: May impact absorption of oral medications requiring rapid onset 2
Side Effect Management
Gradual dose titration minimizes gastrointestinal adverse effects (nausea, vomiting, diarrhea). The slower titration schedule allows assessment of individual tolerance before advancing 2
Comparative Effectiveness
Choose semaglutide 2.4 mg weekly over liraglutide 3.0 mg daily based on:
- Superior weight loss (16.9% vs 8.0%) 1
- Once-weekly vs daily administration
- Proven cardiovascular benefit in obesity without diabetes 1
The conditional recommendation for liraglutide in the 2022 AGA guideline 2 predates the more robust 2025 AACE consensus statement 1 that positions semaglutide as the preferred GLP-1 RA for obesity based on superior efficacy data.